The advertisement promotes LYFGENIA™, a gene therapy aimed at patients aged 12 and older with sickle cell disease (SCD) and a history of vaso-occlusive events (VOEs), highlighting its potential benefits and safety warnings.
Creative Information
| CID: | 546cf140-9dd3-425e-a2b2-20c7fa0c4c0c |
| CRID: | 2_206_538277 |
| Domain: | bluebirdbio.com |
| Seat: | BSW |
| Size: | 300x250 |
| Bid: | $1.35 |
| Timestamp: | 11/18/2025, 9:30:35 PM |
| Declared IAB Categories: |
Analysis
5 succeeded(100% complete)
| Task | Status | Last Updated | Duration | Actions |
|---|---|---|---|---|
| ad_analysis | success | 11/19/2025, 12:18:59 AM | 6.63s | |
| adomain_analysis | success | 11/19/2025, 12:18:41 AM | 2.70s | |
| adomain_capture | success | 11/19/2025, 12:18:38 AM | 11.13s | |
| ad_render | success | 11/19/2025, 12:18:52 AM | 31.04s | |
| brand_mapping | success | 11/18/2025, 9:30:36 PM | 0.79s | |
Analysis Results
Ad Format: banner
Brands: bluebird bio
| Size: | 300x250 | ||||||||||||||||||||||
| Data Transferred: | 1863.36 KB | ||||||||||||||||||||||
| Render Time: | 22.16 Seconds | ||||||||||||||||||||||
| Creative Inferred IAB Categories: |
| ||||||||||||||||||||||
| Creative Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Domain Inferred IAB Categories: |
| ||||||||||||||||||||||
| Domain Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Total Ad Size: | 1882.53 KB | ||||||||||||||||||||||
| Requests Made: |
|
Advertiser Domain
Ad Preview
Raw Ad Markup
<script src="https://tagan.adlightning.com/iponweb/blacklist_script.js" type="text/javascript"></script>
<script src="https://tagan.adlightning.com/iponweb/blocking_script.js" type="text/javascript"></script>
<script type="text/javascript">
function createTagDetails(){
var tagDetails = {};
tagDetails.w = '300';
tagDetails.h = '250';
tagDetails.adServerDetails = {advertiserId: 'kargo', campaignId: '206', creativeId: '206_538277', lineitemId: '0', adServer: 'dfp'};
tagDetails.au = '0';
tagDetails.markupInDom = true;
tagDetails.utilizeParentInfo = true;
var timeBase36 = Date.now().toString(36);
var random = Math.random().toString(36).substr(2).split('')
.map(function (c) {
return (Math.random() < 0.5 ? c.toUpperCase() : c); }) .join('');
tagDetails.currentTagId="adltag_" + timeBase36 + "_" + random;
return tagDetails;
}
var random = "" + Math.round(Math.random() * 1e8);
var clientId = "iponweb";
var site_id = random + "_" + clientId;
window[site_id]={};
window[site_id].tagDetails=createTagDetails();
!function(){"use strict";"blocker"in window||(window.blocker=function(e,n,o,i,t){if((t=t||{}).bw){if(Math.random()<.1){var r="undefined"!=typeof btoa?btoa:String,a="https://"+clientId+"-tagan.adlightning.com",d={siteId:clientId,url:window.top.location.href,tagDetails:window[e],errorData:null,errorMethod:"missing_blocker"},c=encodeURIComponent(JSON.stringify(d)).replace(/%([0-9A-F]{2})/g,function(e,n){return String.fromCharCode("0x"+n)});!function(e){var n=window.Request,o=n&&n.prototype||{};if(navigator&&navigator.sendBeacon)navigator.sendBeacon(e);else if(window.fetch){var i={method:"GET"};"keepalive"in o&&(i.keepalive=!0),window.fetch(e,i)}else{var t=new Image(1,1);"loading"in t&&(t.loading="eager"),t.src=e}}(a+"/error?d="+encodeURIComponent(r(c)))}document.write(n)}})}();
blocker(site_id, "<!--ADL_WRAPPED-->", false, window, {fr: true});
</script>
<ins class='dcmads' style='display:inline-block;width:300px;height:250px' data-dcm-placement='N30602.1172840ADTHEORENTINC8/B34385101.431982541' data-dcm-rendering-mode='script' data-dcm-https-only data-dcm-keywords='e5b24085-c026-11f0-a276-42010ab201aa' data-dcm-click-tracker='https%3A%2F%2Frtb.adentifi.com%2FClicks%3FcrId%3D538277%3BsId%3D821208%3BlId%3D110708%3BcId%3D21536%3BadExchange%3DBidSwitch%3Baction%3Dclick%3BadId%3De5b24085-c026-11f0-a276-42010ab201aa%3BadThdId%3D2a5327130e6b7ed2057e0576a2191409%3BengineId%3D4207510005313797437%3BdIp%3DMTc0LjIxMS4yMjYuMTI5%3BdIpv6%3D%3BadThdIdCode%3DWEB_MD5_V4%3BdealId%3D0%3BgeoId%3D185398%3BinventoryId%3D241313%3BrtdmIndicator%3D1%3Btimestamp%3D1762993374%3Blat%3DMjguNTg%3Blong%3DLTgxLjc1%3Bdma%3DNTM0%3BstateCode%3D%3Bzip%3DMzI5MDk%3Bbsc%3D${CLICK_URL_ENC}%3Bredir%3D' data-dcm-resettable-device-id='' data-dcm-api-frameworks='[APIFRAMEWORKS]' data-dcm-omid-partner='[OMIDPARTNER]' data-dcm-gdpr-applies='gdpr=${GDPR}' data-dcm-gdpr-consent='gdpr_consent=${GDPR_CONSENT_755}' data-dcm-addtl-consent='addtl_consent=${ADDTL_CONSENT}' data-dcm-ltd='false' data-dcm-app-id=''> <script src='https://www.googletagservices.com/dcm/dcmads.js'></script></ins><img src='https://rtb.adentifi.com/Imps?impId=1;adId=e5b24085-c026-11f0-a276-42010ab201aa;lId=110708;sId=821208;cId=21536;crId=538277;adThdId=2a5327130e6b7ed2057e0576a2191409;adExchange=BidSwitch;engineId=4207510005313797437;dealId=0;geoId=185398;inventoryId=241313;rtdmIndicator=1;timestamp=1762993374;property=heavy.com;dIp=MTc0LjIxMS4yMjYuMTI5;dIpv6=;adThdIdCode=WEB_MD5_V4;thirdPartyIdType=1;npiKey=93863320604004979;hhId=517257776;cuid=cuid_fab9e1a0-dcd7-11ef-b46e-12c166c14e3d' style='display:none; width:0px; height:0px;' /><script src="https://tags.bkrtx.com/js/bk-coretag.js"></script><script>bk_addPageCtx("id","cuid_fab9e1a0-dcd7-11ef-b46e-12c166c14e3d");bk_allow_multiple_calls = true;bk_use_multiple_iframes = true;bk_send_statid_payload = true;bk_use_image = true;bk_callback = true;bk_doJSTag(18840, 4);</script><img src='https://sb.scorecardresearch.com/p?c1=9&c2=16077523&c3=2&cs_xi=cuid_fab9e1a0-dcd7-11ef-b46e-12c166c14e3d&rn=e5b24085-c026-11f0-a276-42010ab201aa' height='0' width='0' /><span id="te-clearads-js-adtheorent01cont538277"><script type="text/javascript" src="//choices.truste.com/ca?pid=adtheorent01&aid=adtheorent01&cid=21536&c=adtheorent01cont538277&w=300&h=250&js=pmw0&plc=tr&uid=2a5327130e6b7ed2057e0576a2191409"></script></span><img src="https://us-east-sync.bidswitch.net/sync?ssp=kargo&dsp_id=206&imp=1" alt=" " style="display:none"/>Creatives
